CIK 0001664710
- Non-accelerated filer
- Smaller reporting company
Keros Therapeutics, Inc.
Sign in to watch- Ticker
- KROS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 811173868
- Phone
- +1 617-314-6297
- Business address
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- 4 Option exercise Director acquired 7,176 shares (option exercise)
- 3/A Insider 3/A
- 3/A Insider 3/A
- 3/A Insider 3/A
- 4 Open-market sale Chief Scientific Officer sold 46,034 shares at $30.00 ($1,381,020)
- 4 Open-market sale Chief Scientific Officer sold 1,916 shares at $30.00 ($57,480)
- 4 Option exercise Chief Scientific Officer acquired 9,400 shares (option exercise)
- 4 Option exercise Chief Executive Officer acquired 5,000 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Scientific Officer sold 5,300 shares at an average $41.90 ($222,050)
- 4 Open-market sale Chief Scientific Officer sold 5,300 shares at an average $62.77 ($332,705)
- 4 Open-market sale Chief Operating Officer sold 1,728 shares at $65.00 ($112,320)
- 4 Open-market sale Chief Scientific Officer sold 7,950 shares at $60.00 ($477,000)
- 4 Open-market sale Chief Operating Officer sold 864 shares at an average $57.49 ($49,675)
- 4 Open-market sale Chief Scientific Officer sold 2,650 shares at an average $53.38 ($141,449)
Page 6 of 11 · 207 filings